– A maxirisarcimento from 1,200 million euro as required by the Ministry of Health to pharmaceutical companies Novartis, Roche and Hoffmann for the story of the marketing of the drugs Lucentis and Avastin. The sponsor of the competition had in fact qualified as “a horizontal restrictive” free-market behavior of companies to sell Lucentis, Avastin more expensive than equivalent. Asked 14 million to Pfizer.
deliberation about the scandal of the Lucentis-Avastin was prepared in February this year, and it is defined precisely the behavior of the company Hoffman-La Roche Ltd., Roche Spa, Novartis AG and Novartis Farma Spa as “a horizontal agreement restricting competition aimed at the commercialization of the drug Lucentis, very more expensive drug Avastin, equivalent to it. ” Following this document was required to pharmaceutical companies involved “compensation for all damage to property”, estimated at 45 million in 2012, 540 in 2013 and 615 in 2014, and those “non-property wrongfully caused to the NHS.”
case Xalatan – For Pfizer, the decision of the Competition January 11, 2012, upheld on judicial review by the State Council on February 12, said the Ministry of Health in a statement, “has defined the conduct engaged in by Pfizer ‘characterized by a clear and insisted anti-competitive intent, seeking to delay the marketing of generic drugs, even with considerable damage to the national health service.’” As a result the ministry has requested “damages, both the balance sheet (EUR 14 million) and non-pecuniary, suffered by the National Health Service in respect of the Italian company Pfizer Ltd., Pfizer Inc. and Pfizer Health AB, due to the behavior of abuse of dominant position held by them in connection with the marketing of the drug Xalatan. “
Roche replied:” Figures unreal “ – La Roche expresses” his whole surprise “for the request compensation for damages by the Ministry of Health and precise in a statement that “the figures still seem unreal.” The drugmaker added that “the measure upon which the request is the subject of an appeal before the TAR of Lazio and that there is a judgment, not of first degree, awarded to companies that have the responsibility for the alleged damage, nor does it quantify the damage “.
Novartis’ request compensation unfounded” – For Novartis “any claim is groundless as well as the figures given in the statement of the Ministry, which there is no correspondence with the reality of the facts. ” So says the claim that the pharmaceutical company in a statement said that “will make use of their rights of defense in all relevant fora.” “The spending generated by Lucentis to the NHS in January-September 2013 – Novartis precise – was equal to 38.6 million euro, in line with the data recorded in 2012.”
No comments:
Post a Comment